Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Liraglutide

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

Novo Nordisk · Phase 3 · Completed · Enrollment 153

NCT01234649

Y axis: Change in body weight from baseline, %

0-5-10048121620243648607284Metformin XR plus liraglutide, week 84, -7.2%Metformin XR plus liraglutideMetformin XR plus placebo, week 84, -3.1%Metformin XR plus placebo

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Metformin XR plus liraglutide: week 84 -7.2%
  • Metformin XR plus placebo: week 84 -3.1%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.